Acadia Pharmaceuticals Loses R&D Chief in Year-End Retirement
Event summary
- Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development at Acadia Pharmaceuticals, will retire by year-end for personal reasons.
- Dr. Thompson will remain as a consultant through at least the end of 2026 to ensure continuity during key clinical trials.
- Acadia has initiated a search for her successor to maintain R&D momentum in neurological and rare disease programs.
- Phase 2 clinical studies for remlifanserin in Alzheimer’s disease psychosis (ADP) and Lewy Body Dementia Psychosis (LBDP) are ongoing.
The big picture
Acadia Pharmaceuticals faces a critical leadership transition as it navigates key clinical milestones for its flagship remlifanserin program. The departure of Dr. Thompson, who has been instrumental in shaping the company’s R&D strategy, underscores the challenges biopharmaceutical firms face in maintaining scientific continuity during executive transitions. The success of Acadia’s pipeline hinges on its ability to seamlessly integrate new leadership while sustaining momentum in neurological and rare disease research.
What we're watching
- Leadership Continuity
- How Acadia’s ability to recruit a strong successor will impact its R&D pipeline and clinical trial execution.
- Clinical Trial Momentum
- Whether the Phase 2 readouts for remlifanserin in ADP and LBDP will meet expectations despite leadership changes.
- Pipeline Advancement
- The pace at which Acadia can advance its other mid- to late-stage programs without Dr. Thompson’s direct oversight.
Related topics